CN115397827A - Fgfr4抑制剂的盐型、晶型及其用途 - Google Patents

Fgfr4抑制剂的盐型、晶型及其用途 Download PDF

Info

Publication number
CN115397827A
CN115397827A CN202180021447.5A CN202180021447A CN115397827A CN 115397827 A CN115397827 A CN 115397827A CN 202180021447 A CN202180021447 A CN 202180021447A CN 115397827 A CN115397827 A CN 115397827A
Authority
CN
China
Prior art keywords
cancer
salt
ray powder
salt form
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180021447.5A
Other languages
English (en)
Other versions
CN115397827B (zh
Inventor
高金恒
徐晓峰
陈亮
孙中心
张赟
刘湘永
丁列明
王家炳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betta Pharmaceuticals Co Ltd
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of CN115397827A publication Critical patent/CN115397827A/zh
Application granted granted Critical
Publication of CN115397827B publication Critical patent/CN115397827B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/14—Adipic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明涉及结构式I所示化合物的晶型和/或马来酸盐、磷酸盐、L‑酒石酸盐、和己二酸盐，及各盐型的多种晶型，其制备方法及其应用。
Figure DDA0003847286850000011

Description

PCT国内申请，说明书已公开。

Claims (30)

  1. PCT国内申请，权利要求书已公开。
CN202180021447.5A 2020-03-27 2021-03-26 Fgfr4抑制剂的盐型、晶型及其用途 Active CN115397827B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020102340268 2020-03-27
CN202010234026 2020-03-27
CN2021103047230 2021-03-22
CN202110304723 2021-03-22
PCT/CN2021/083204 WO2021190623A1 (zh) 2020-03-27 2021-03-26 Fgfr4抑制剂的盐型、晶型及其用途

Publications (2)

Publication Number Publication Date
CN115397827A true CN115397827A (zh) 2022-11-25
CN115397827B CN115397827B (zh) 2024-03-15

Family

ID=77891326

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180021447.5A Active CN115397827B (zh) 2020-03-27 2021-03-26 Fgfr4抑制剂的盐型、晶型及其用途

Country Status (7)

Country Link
US (1) US20240174681A1 (zh)
EP (1) EP4130004A4 (zh)
JP (1) JP2023519011A (zh)
KR (1) KR20220159457A (zh)
CN (1) CN115397827B (zh)
TW (1) TW202144354A (zh)
WO (1) WO2021190623A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104271576A (zh) * 2012-02-23 2015-01-07 艾伯维公司 激酶的吡啶并嘧啶酮抑制剂
WO2018004258A1 (ko) * 2016-06-28 2018-01-04 한미약품 주식회사 신규한 헤테로시클릭 유도체 화합물 및 이의 용도
WO2018153373A1 (zh) * 2017-02-27 2018-08-30 贝达药业股份有限公司 Fgfr抑制剂及其应用
WO2020063788A1 (zh) * 2018-09-27 2020-04-02 贝达药业股份有限公司 Fgfr4抑制剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011038579A1 (en) * 2009-09-30 2011-04-07 Zhejiang Beta Pharma Inc. Compounds and compositions as protein kinase inhibitors
ES2924111T3 (es) 2013-10-25 2022-10-04 Blueprint Medicines Corp Inhibidores del receptor del factor de crecimiento de fibroblastos
CN110022900A (zh) * 2016-09-08 2019-07-16 蓝图药品公司 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
WO2020038458A1 (zh) * 2018-08-23 2020-02-27 如东凌达生物医药科技有限公司 一类稠环三氮唑类化合物、制备方法和用途
EP3936509A4 (en) * 2019-03-08 2022-03-30 Shouyao Holdings (Beijing) Co., Ltd. FGFR4 KINASE INHIBITOR, METHOD FOR PREPARATION AND USE

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104271576A (zh) * 2012-02-23 2015-01-07 艾伯维公司 激酶的吡啶并嘧啶酮抑制剂
WO2018004258A1 (ko) * 2016-06-28 2018-01-04 한미약품 주식회사 신규한 헤테로시클릭 유도체 화합물 및 이의 용도
WO2018153373A1 (zh) * 2017-02-27 2018-08-30 贝达药业股份有限公司 Fgfr抑制剂及其应用
WO2020063788A1 (zh) * 2018-09-27 2020-04-02 贝达药业股份有限公司 Fgfr4抑制剂及其应用
CN112771049A (zh) * 2018-09-27 2021-05-07 贝达药业股份有限公司 Fgfr4抑制剂及其应用

Also Published As

Publication number Publication date
WO2021190623A1 (zh) 2021-09-30
EP4130004A4 (en) 2024-04-10
CN115397827B (zh) 2024-03-15
US20240174681A1 (en) 2024-05-30
JP2023519011A (ja) 2023-05-09
EP4130004A1 (en) 2023-02-08
KR20220159457A (ko) 2022-12-02
TW202144354A (zh) 2021-12-01

Similar Documents

Publication Publication Date Title
CN107382879B (zh) 一种嘧啶类化合物、egfr抑制剂及其应用
WO2017046216A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
CN112771049B (zh) Fgfr4抑制剂及其应用
CN110551142A (zh) 一种稠环嘧啶类化合物的盐、晶型及其制备方法和应用
CN115667241B (zh) TrkA抑制剂
CN115397827B (zh) Fgfr4抑制剂的盐型、晶型及其用途
JP2021508319A (ja) Ａｋｔ阻害剤としての塩形態及びその結晶形態
CN110283174B (zh) 一类PI3Kδ抑制剂及其用途
JP7118349B2 (ja) ｃ－ＭＥＴ阻害剤の結晶形、及びその塩形、並びに調製方法
CN116018343A (zh) 一种吡啶并嘧啶化合物的晶型
CN116171156A (zh) 含嘧啶基团的三并环类化合物的盐型、晶型及其制备方法
JP2022517396A (ja) Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
CN107344925B (zh) 氘代二苯基氨基-三氟甲基嘧啶化合物
JP7432739B2 (ja) アザインドール誘導体の結晶形及びその応用
JP7496440B2 (ja) Ｔｒｋａ阻害剤
WO2023202706A1 (zh) 硒杂环类化合物的盐型和晶型及其应用
US20210340142A1 (en) Salt form and crystal form of novel azatricyclic compound and use thereof
TW202313034A (zh) Egfr抑制劑的鹽、晶型及其組合物和應用
JP2024037713A (ja) Ｆｇｆｒ３阻害剤の共結晶形態
CN117247382A (zh) 吡啶并嘧啶酮化合物的晶型
CN117321047A (zh) 化合物的晶型、含晶型组合物及其制备方法和应用
CN114075135A (zh) 含邻氨基吡啶炔基的化合物的盐及其制备方法和应用
CN115340529A (zh) 一种rock抑制剂的酸加成盐及盐的晶型、组合物和药物用途
CN116867491A (zh) 3,4-二氢异喹啉类化合物的盐及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080650

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant